Seres Therapeutics, Inc.
MCRB
$7.59
-$0.29-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 62.09% | 285.51% | -170.61% | 43.61% | 40.04% |
| Total Depreciation and Amortization | -2.35% | -16.63% | -7.01% | 11.36% | 54.27% |
| Total Amortization of Deferred Charges | -100.00% | 17.81% | 223.33% | 148.66% | 169.08% |
| Total Other Non-Cash Items | -88.80% | -1,343.21% | -59.46% | -2.54% | -140.73% |
| Change in Net Operating Assets | -95.76% | 57.90% | -1,036.41% | 52.67% | -442.13% |
| Cash from Operations | 18.14% | 41.47% | -160.33% | 53.99% | 10.20% |
| Capital Expenditure | 89.74% | 92.82% | 91.97% | 98.48% | 74.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -88.08% | -- | -100.00% |
| Cash from Investing | 89.74% | 7,954.37% | -87.62% | -102.26% | -114.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.98% | 1,080.46% | -100.00% | 231.72% | 387.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -72.98% | -7,783.37% | -100.00% | 231.72% | 39.85% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.23% | 92.61% | -128.59% | 75.75% | 0.99% |